Imidazoline Binding Sites in the Endocrine Pancreas: Can They Fulfil Their Potential as Targets for the Development of New Insulin Secretagogues?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|7|14|1413-1431

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.7, Iss.14, 2001-09, pp. : 1413-1431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites

By Chan S.L.F. Pallett A.L. Clews J. Ramsden C.A. Chapman J.C. Kane C. Dunne M.J. Morgan N.G.

European Journal of Pharmacology, Vol. 355, Iss. 1, 1998-08 ,pp. : 67-76

Elsevier

Access to resources Recommend Favorite

New non-sulfonylurea insulin secretagogues

By Dunning B.E.

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 8, 1997-08 ,pp. : 1041-1048

Informa Healthcare

Access to resources Recommend Favorite

Imidazoline binding sites in Huntington's and Parkinson's disease putamen

By Reynolds G.P. Boulton R.M. Pearson S.J. Hudson A.L. Nutt D.J.

European Journal of Pharmacology, Vol. 301, Iss. 1, 1996-04 ,pp. : 19-21

Elsevier

Access to resources Recommend Favorite

New potential targets for antifungal development

By Wills E.A. Redinbo M.R. Perfect J.R. Poeta M.D.

Expert Opinion on Therapeutic Targets, Vol. 4, Iss. 3, 2000-06 ,pp. : 265-296

Informa Healthcare

Access to resources Recommend Favorite

Receptor ligands and imidazoline secretagogues mediate their insulin secretory effects by activating distinct receptor systems in isolated islets

By Chan S.L.F. Morgan N.G.

European Journal of Pharmacology, Vol. 350, Iss. 2, 1998-06 ,pp. : 267-272

Elsevier

Access to resources Recommend Favorite